Accelerate Research
Evidentic empowers scientists with clinical-grade aliquots from original therapeutics, fueling scientific breakthroughs. We source licensed molecules for research and early drug development, saving time and cost for our customers.
Our mission: empower drug discovery
At Evidentic, we are committed to bridging the gap between early-stage pharmaceutical research and the commercialization of therapeutics by providing researchers with reliable access to clinical-grade reference compounds. Our mission is to accelerate drug discovery and development by providing customized solutions that meet the diverse needs of our customers – from large pharmaceutical companies to academic institutions. Our creative solution is to support the advancement of global health by ensuring that breakthrough research has the tools it needs to succeed.
Our vision is to revolutionize research access worldwide
At Evidentic, we promise reliable access to high-quality, clinical-grade therapeutic molecules, innovative solutions tailored to your research needs, and unwavering support along your scientific journey.
time efficient
Researchers save an average of 8 weeks on sourcing critical therapeutic molecules with Evidentic's streamlined sourcing process and our unique service.
Batch library
Fuel groundbreaking research with Evidentic's comprehensive library of over 70 therapeutic molecules, plus various batches and biosimilars.
Worldwide sourcing
Evidentic already provides researchers in 38 countries worldwide with aliquots of licensed therapeutics, accelerating scientific progress on a global scale.
A journey of innovation: Evidentic's history
From a spark of scientific curiosity to a leading provider of clinical-grade molecules in small entities, Evidentic's story is one of continuous growth. Follow our story and learn how our commitment to scientific progress has shaped the future of life science research.
09.03.2017: Evidentic was founded in Berlin/Germany.
This marked the beginning of our journey in revolutionizing the pharmaceutical industry.
09/2017: First clinical-grade molecules available! Including Bavacizumab/Avastin® & Daratumumba/Darzalex®
This milestone ensured we provided high-quality pharmaceutical products.
28.03.2018: Licensed for business! Evidentic obtains its wholesale license.
This allowed us to expand our market reach and distribution capabilities.
10/2018: Evidentic attends its first major conference: CPHI Frankfurt.
Showcasing our innovations to a global audience.
07/2019: Expanding globally! Evidentic receives orders from all over the world.
Entering the global market was a major achievement for Evidentic.
06/2021: New offerings! Evidentic adds first ADCs (Antibody-drug conjugates) to its stock.
The ADCs Brentuximab vedotin/Adcetris® & Trastuzumab Emtansine/Kadcyla® proofed our sourcing expertise.
04/2022: Strategic collaboration! Evidentic partners with Biofidus AG.
New Partnership to enhance our product offerings and expertise.
04/2022: Enhancing services! Evidentic offers new analytical data services with Biofidus AG.
Offering comprehensive analytical date of clinical-grade molecules to our customers.
02/2024: Growing locations meets In-house expertise! Evidentic establishes its own laboratory.
This milestone enables us to conduct in-house aliquotation and logistics.
Our Team
Join the Team
Evidentic empowers researchers with the building blocks of scientific discovery: high-quality samples of therapeutic molecules. We're on a mission to make these resources readily available, saving researchers time and money so they can focus on what truly matters – pushing the boundaries of science.